Cargando…
AZD3293: A Novel, Orally Active BACE1 Inhibitor with High Potency and Permeability and Markedly Slow Off-Rate Kinetics
A growing body of pathological, biomarker, genetic, and mechanistic data suggests that amyloid accumulation, as a result of changes in production, processing, and/or clearance of brain amyloid-β peptide (Aβ) concentrations, plays a key role in the pathogenesis of Alzheimer’s disease (AD). Beta-secre...
Autores principales: | Eketjäll, Susanna, Janson, Juliette, Kaspersson, Karin, Bogstedt, Anna, Jeppsson, Fredrik, Fälting, Johanna, Haeberlein, Samantha Budd, Kugler, Alan R., Alexander, Robert C., Cebers, Gvido |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
IOS Press
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4927864/ https://www.ncbi.nlm.nih.gov/pubmed/26890753 http://dx.doi.org/10.3233/JAD-150834 |
Ejemplares similares
-
Molecular Docking and Dynamic Simulation of AZD3293 and Solanezumab Effects Against BACE1 to Treat Alzheimer's Disease
por: Hassan, Mubashir, et al.
Publicado: (2018) -
Clinical Bioavailability of the Novel BACE1 Inhibitor Lanabecestat (AZD3293): Assessment of Tablet Formulations Versus an Oral Solution and the Impact of Gastric pH on Pharmacokinetics
por: Ye, Naidong, et al.
Publicado: (2018) -
3293 Region Specific Dysregulation of Dopaminergic Signaling in Mice Displaying Excessive Over-Grooming
por: Foster, Daniel, et al.
Publicado: (2019) -
The participation rate of migrant women in gestational diabetes screening in Austria: a retrospective analysis of 3293 births
por: Weiss, Christoph, et al.
Publicado: (2018) -
Prolonged labour associated with lower expression of syndecan 3 and connexin 43 in human uterine tissue
por: Cluff, Ann Hjelm, et al.
Publicado: (2006)